Pacifica Partners’s Biogen BIIB Stock Holding History

Pacifica Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-15	Closed	-$3K	–	472
2022 Q2	$3K	Hold	15	–	–	﹤0.01%	400
2022 Q1	$3K	Hold	15	–	–	﹤0.01%	400
2021 Q4	$4K	Buy	+15	New	+$3.86K	﹤0.01%	378

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Pacifica Partners's BIIB Position: Q3 2022 in Review

Pacifica Partners sold out of Biogen (BIIB) in Q3 2022, closing a stake of 15 shares — an estimated $3K sold.

Pacifica Partners first reported a position in BIIB in Q4 2021 and held it in 3 quarters. The position peaked at $4K in Q4 2021. 985 funds tracked by Wall St. Rank hold BIIB as of Q3 2022.

Pacifica Partners reported no remaining Biogen position as of Q3 2022 after selling out during the quarter.
Pacifica Partners sold 15 Biogen shares in Q3 2022, an estimated $3K.
Pacifica Partners first reported a position in Biogen in Q4 2021 and held it in 3 quarters.
Pacifica Partners's Biogen position peaked at $4K in Q4 2021.
985 funds tracked by Wall St. Rank held Biogen as of Q3 2022.

Based on Pacifica Partners's 13F filing for Q3 2022, filed 14 Oct 2022.